McIlrath & Eck’s Helus Pharma Inc. Common Stock HELP Stock Holding History

McIlrath & Eck’s Portfolio HELP Stock Details HELP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48	Hold	10	–	–	﹤0.01%	1598
2025 Q4	$82	Hold	10	–	–	﹤0.01%	971
2025 Q3	$59	Hold	10	–	–	﹤0.01%	932
2025 Q2	$84	Hold	10	–	–	﹤0.01%	922
2025 Q1	$63	Hold	10	–	–	﹤0.01%	921
2024 Q4	$88	Hold	10	–	–	﹤0.01%	963
2024 Q3	$89	Sell	10 -1	-9%	-$10	﹤0.01%	966
2024 Q2	$108	Hold	11	–	–	﹤0.01%	935
2024 Q1	$165	Hold	11	–	–	﹤0.01%	920
2023 Q4	$164	Hold	11	–	–	﹤0.01%	906
2023 Q3	$213	Hold	11	–	–	﹤0.01%	865
2023 Q2	$151	Hold	11	–	–	﹤0.01%	875
2023 Q1	$154	Hold	11	–	–	﹤0.01%	905
2022 Q4	$119	Hold	11	–	–	﹤0.01%	863
2022 Q3	$0	Hold	11	–	–	﹤0.01%	847
2022 Q2	$0	Hold	11	–	–	﹤0.01%	838
2022 Q1	$0	Hold	11	–	–	﹤0.01%	814
2021 Q4	$0	Hold	11	–	–	﹤0.01%	805
2021 Q3	$1K	Buy	+11	New	+$963	﹤0.01%	754

Other funds holding HELP

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

McIlrath & Eck's HELP Position: Q1 2026 in Review

McIlrath & Eck held its Helus Pharma Inc. Common Stock (HELP) position steady in Q1 2026 at 10 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

McIlrath & Eck first reported a position in HELP in Q3 2021 and has held it in 19 quarters since. The position peaked at $1K in Q3 2021. 81 funds tracked by Wall St. Rank hold HELP as of Q1 2026.

McIlrath & Eck held 10 shares of Helus Pharma Inc. Common Stock worth $48 as of Q1 2026.
McIlrath & Eck left its Helus Pharma Inc. Common Stock share count unchanged in Q1 2026.
Helus Pharma Inc. Common Stock made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1598 holding.
McIlrath & Eck first reported a position in Helus Pharma Inc. Common Stock in Q3 2021 and has held it in 19 quarters since.
McIlrath & Eck's Helus Pharma Inc. Common Stock position peaked at $1K in Q3 2021.
81 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.